Compare NX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | ABUS |
|---|---|---|
| Founded | 1927 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.6M | 839.5M |
| IPO Year | 2008 | 2008 |
| Metric | NX | ABUS |
|---|---|---|
| Price | $17.96 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $28.00 | $5.00 |
| AVG Volume (30 Days) | 418.7K | ★ 1.9M |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $1,837,641,000.00 | $14,083,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | $239.71 |
| P/E Ratio | ★ N/A | $5.07 |
| Revenue Growth | 43.81 | ★ 128.21 |
| 52 Week Low | $11.04 | $3.04 |
| 52 Week High | $22.90 | $5.10 |
| Indicator | NX | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 54.41 |
| Support Level | $16.90 | $4.15 |
| Resistance Level | $18.07 | $4.60 |
| Average True Range (ATR) | 0.89 | 0.17 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 80.60 | 56.25 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.